HK Stock Market Move | SBP GROUP (01177) rose nearly 5% in early trading as TQB6426 received FDA approval to initiate clinical trials for the treatment of advanced malignant tumors.

SBP GROUP (01177) rose nearly 5% in early trading. As of this writing, it is up 3.99%, trading at HKD 5.47, with a turnover of HKD 107 million. On the news front, SBP GROUP's subsidiary, Zhengda Tianqing, has recently received default approval for clinical trials from the U.S. Food and Drug Administration (FDA) for its innovatively developed GPC3 antibody-drug conjugate (ADC) TQB6426, which is intended for the treatment of advanced malignancies. With this, TQB6426 has secured clinical access qualifications in the two core pharmaceutical markets of China and the United States, marking an important milestone in the global development of the company's innovative drugs. Additionally, Zhengda Tianqing announced that the Phase III clinical study results for its independently developed, dual-antibody ADC new drug TQB2102, designed for the treatment of HER2 low-expressing recurrent/metastatic breast cancer, have reached the predefined endpoints as determined by an independent data monitoring committee. This is reportedly the first successful Phase III clinical study of its kind globally, with the potential to enable precise treatment for breast cancer populations and provide new treatment options for breast cancer patients with specific molecular subtypes.